Signal Advisors Wealth LLC Acquires 7,696 Shares of Halozyme Therapeutics, Inc. $HALO

Signal Advisors Wealth LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 7,696 shares of the biopharmaceutical company’s stock, valued at approximately $850,000.

A number of other hedge funds have also recently bought and sold shares of HALO. Bank of America Corp DE acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at about $214,504,000. William Blair Investment Management LLC bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at about $196,540,000. Jupiter Topco LLC bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at about $105,570,000. Caisse de depot et placement du Quebec acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $83,940,000. Finally, Congress Asset Management Co. grew its stake in shares of Halozyme Therapeutics by 85.6% in the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after purchasing an additional 1,052,509 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of research reports. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Zacks Research upgraded Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Finally, HC Wainwright raised their price objective on Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $96.50.

Insiders Place Their Bets

In other news, Director Matthew L. Posard sold 18,996 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total value of $2,046,629.04. Following the completion of the sale, the director owned 58,839 shares in the company, valued at $6,339,313.86. This represents a 24.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. This trade represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 125,852 shares of company stock worth $13,538,046. Corporate insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $121.51 on Friday. The stock’s 50-day moving average price is $108.68 and its two-hundred day moving average price is $84.66. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The company has a market cap of $13.79 billion, a PE ratio of 23.70, a PEG ratio of 0.44 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $122.33.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. During the same period in the prior year, the firm earned $1.54 earnings per share. The business’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, analysts predict that Halozyme Therapeutics, Inc. will post 8.31 EPS for the current year.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks upgraded HALO from “Hold” to “Strong Buy,” providing a fresh endorsement of the company’s growth outlook and potentially attracting additional buying interest.
• Positive Sentiment: TD Cowen raised its price target to $130 from $105 while maintaining a Buy rating. The higher target suggests analysts see further appreciation potential after the stock’s recent rally. TD Cowen Forecasts Strong Price Appreciation for Halozyme Therapeutics Stock
• Positive Sentiment: FDA approval of Roche’s Tecentriq Hybreza for stage III mismatch-repair-deficient colon cancer expands the commercial opportunity for a Halozyme-enabled product. The approval could support future royalty revenue, with clinical data showing a 50% reduction in recurrence or death risk versus chemotherapy alone. Partner-drug approval, patent win and bullish analyst call
• Positive Sentiment: A Dutch court injunction blocking Merck’s Keytruda SC manufacturing and sales in several European markets reduces a competitive and intellectual-property overhang for Halozyme’s technology.
• Positive Sentiment: Zacks highlighted Halozyme’s solid growth characteristics as a reason growth investors should not overlook the stock. Three reasons growth investors should not overlook Halozyme
• Neutral Sentiment: Institutional positioning was mixed: 354 investors added HALO shares while 266 reduced their holdings. This indicates continued interest but also some profit-taking and portfolio rebalancing.
• Negative Sentiment: Insider activity was a potential cautionary signal, with executives reporting sales and no purchases over the past six months. These transactions may reflect profit-taking rather than a change in business fundamentals, but they could temper sentiment after the strong advance.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.